Pituitary surgery during Covid-19: a first hand experience and evaluation.
J Endocrinol Invest
; 44(3): 635-636, 2021 Mar.
Article
em En
| MEDLINE
| ID: mdl-32651894
ABSTRACT
PURPOSE:
During the Covid-19 pandemic every hospital has had to change its internal organization. Different institutions have highlighted the risks connected with endoscopic endonasal surgery. The goal of this paper is to illustrate the feasibility of pituitary region surgery during the SARS-CoV-2 pandemic.METHODS:
After two negative Covid tests were obtained, three patients with macro GH-secreting tumors, and two patients with micro ACTH-secreting tumors resistant to medical treatment underwent surgery during the pandemic. During the surgery, every patient was treated as if they were positive.RESULTS:
Neither operator, nor patient have developed Covid symptoms. The two neurosurgeons performing the operations underwent two Covid swab, which resulted negative.CONCLUSIONS:
Pituitary surgery is a high risk non-urgent surgery. However, the method described has so far been effective and is safe for both patients and healthcare providers.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Adenoma
/
Controle de Infecções
/
Procedimentos Neurocirúrgicos
/
Adenoma Hipofisário Secretor de ACT
/
Adenoma Hipofisário Secretor de Hormônio do Crescimento
/
COVID-19
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Humans
País/Região como assunto:
Europa
Idioma:
En
Revista:
J Endocrinol Invest
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Itália